As the second leading cause of death worldwide, cancer is a focal point in both clinical research and health care fields, but not all cancers are created equal. While some cancers are now much less deadly due to recent medical ...
Jan 14, 2019
0
3
Researchers have identified a new potential immunotherapy target in pancreatic cancer, which so far has been notoriously resistant to treatment with immune checkpoint blockade drugs effective against a variety of other cancers.
Jan 11, 2019
0
14
Researchers at the Johns Hopkins Kimmel Cancer Center discovered a combination of a cancer vaccine with two checkpoint drugs reduced pancreatic cancer tumors in mice, demonstrating a possible pathway for treatment of people ...
Dec 18, 2018
0
14
Imagine being at a packed concert hall with a mosh pit full of dancers creating a wall against outsiders. When targeted drugs try to make their way toward a pancreas tumor, they encounter a similar obstacle in stiff tissue ...
Dec 06, 2018
0
3
Patients diagnosed with pancreatic cancer face a poor prognosis because the tumor forms dense scar-like tissue that is difficult for chemotherapy drugs to penetrate, but a new model may help researchers develop new therapies.
Dec 04, 2018
0
6
Pancreatic cancer has a grim prognosis. It is usually detected after the disease has spread, and chemotherapy tends to do little to slow the cancer's growth. Even with treatment, most patients live only about six months after ...
Oct 26, 2018
0
4
Researchers at The University of Texas MD Anderson Cancer Center have shed new light on why pancreatic tumors are so resistant to therapy. The answer may lie in treating a protein found in the scar-type tissue called stroma ...
Oct 24, 2018
0
88
A treatment for highly aggressive and commonly fatal pancreatic cancer is being developed, reports a University of Houston researcher who has designed a new medicine that can inhibit two of the major pathways of the deadly ...
Sep 11, 2018
0
529
A compound discovered at Sanford Burnham Prebys Medical Discovery Institute (SBP) has advanced into a Phase 1 trial for metastatic pancreatic cancer. Called CEND-1 (scientifically known as iRGD), the compound was exclusively ...
Aug 21, 2018
0
42
A University of North Carolina Lineberger Comprehensive Cancer Center study may provide insights into how to overcome barriers to using immune-based treatments for pancreatic cancer, the third most deadly cancer in the United ...
Aug 06, 2018
0
76
